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ORIGINAL ARTICLE
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BACKGROUND The diagnosis of dengue is complex. Until recently, only specialised laboratories were able to confirm dengue 
infection. However, this has changed with the newly available immunochromatographic rapid tests. Early diagnosis is of great 
interest, and point-of-care rapid tests have been increasingly used in Brazil. Most of those tests have not undergone validation in 
the Brazilian population. In this context, we decided to evaluate a rapid test introduced in the Federal District (FD).
OBJECTIVES To estimate the accuracy and reliability of the SD Bioeasy Dengue Duo rapid test and its components to detect 
dengue infections in a consecutive sample of symptomatic residents in the FD, Brazil.
METHODS In total, 1353 venous blood samples were collected between 2013 and 2014. Two hundred and six positive samples (cases) 
and 246 negative samples (non cases) were required for sensitivity and specificity estimation, respectively; for agreement evaluation, 
we used 401 samples. The reference standard used was a composite of MAC-ELISA, virus isolation and real-time polymerase chain 
reaction (RT-qPCR). The evaluation was conducted prospectively under field conditions in the public health units of the FD.
FINDINGS The results for the overall accuracy of the rapid test (NS1/IgM combined) showed 76% sensitivity and 98% specificity. 
The sensitivity for the NS1 component (67%) was better than that for the IgM component (35%). The positive likelihood ratio was 
46, and the negative likelihood ratio was 0.24. The reliability of the test (NS1/IgM combined) demonstrated crude agreement of 
98% (Kappa index 0.94).
MAIN CONCLUSIONS The present phase III, large-scale validation study demonstrates that the rapid test SD Bioeasy Dengue Duo has 
moderate sensitivity (NS1/IgM combined) and high specificity. Therefore, the test is useful in confirming the diagnosis of dengue, but 
not enough to rule out the diagnosis. Our results also suggest that Dengue virus (DENV) viral load estimated through the RT-qPCR and 
antibody level measured through the MAC-ELISA could have had a direct influence on the accuracy of the rapid test.
Key words - dengue - dengue diagnosis - immunochromatographic rapid tests - accuracy
doi: 10.1590/0074-02760170433 
Financial support: LACEN 
† In memoriam 
+ Corresponding author: paulopradounb@yahoo.com.br 
Received 11 October 2017 
Accepted 18 May 2018
Dengue is the most disseminated arthropod-borne vi-
ral disease among humans. The World Health Organiza-
tion (WHO) estimates that 50 million people are infected 
yearly in the world and approximately 2.5 billion live in 
areas with high-risk of infection. The number of cases has 
increased approximately 30-fold for the past 50 years, and 
the reason is likely related to human population increases 
and urbanisation (WHO 2009). These numbers are prob-
ably underestimated, as other authors using cartographic 
approaches estimate approximately 390 million dengue 
infections per year, of which 96 million would be apparent 
(Bhatt et al. 2013). Cities create larvae developing natural 
reservoirs for Aedes aegypti, the main vector for Dengue 
virus (DENV) (Wang and Sekaran 2010, Gubler 2011). 
There are four distinct viral serotypes that cause dengue 
(DENV-1, DENV-2, DENV-3 and DENV-4). The four se-
rotypes can cause infection in humans and are globally 
distributed (Messina et al. 2014) causing either asymp-
tomatic or symptomatic infections, some of them with 
lethal outcomes (Paixão et al. 2015, Tassara et al. 2017).
The new WHO classification for dengue severity is di-
vided into Dengue without Warning Signs, Dengue with 
Warning Signs, and Severe Dengue to better and more 
precisely define the progression of the disease and set up 
proper public policies (Horstick et al. 2015). In Brazil, the 
Health Ministry advises insect vector control to reduce 
virus transmission and early case detection to reduce the 
lethality rate in severe cases (Cavalcanti et al. 2013). Cur-
rent dengue treatment is based on isotonic fluid replace-
ment since no specific antiviral intervention is available 
(Guzmán and Kourí 2004). There is a registered vaccine 
in Brazil with low efficacy and no effect evaluation in 
children and old-aged people (Shim 2017). Consequently, 
the accurate and reliable diagnosis is of great interest for 
clinical management and avoiding disease progression to-
wards severe manifestations (Guzmán et al. 2010).
Dengue diagnosis remains a major challenge for 
most Latin American countries. The laboratory confir-
mation of the diagnosis is complex and, until recently, 
only specialised laboratories were able to confirm the 
infection. However, this scenario has changed gradually 
with the availability of immunochromatographic rapid 
tests (RDTs), which detect dengue infection quickly. 
Paulo Sousa Prado et al.2|8
RDTs can be applied in the lab or as point-of-care tools. 
Among several techniques available for dengue diagno-
sis, the immunochromatographic rapid tests have been 
increasingly used in Brazil. Nonetheless, most of the 
available tests have not undergone extensive validation 
in the Brazilian population. Additionally, precise accu-
racy data are not currently available for clinicians acting 
in routine clinical settings (Osorio et al. 2015). There-
fore, this research aims to estimate the accuracy and 
reliability of the SD Bioeasy Dengue Duo (Standard Di-
agnostic Inc., Korea) and its components to detect acute 
dengue infection in a consecutive sample of symptom-
atic residents in the Federal District (FD), Brazil.
MATERIALS AND METHODS
Study design - The study was divided into two com-
ponents: (1) a large-scale phase III validation carried out 
in a consecutive sample of dengue-suspicious patients 
from the target population (Schilling et al. 2004); and 
(2) a reliability study among the different public units 
where samples were collected. The samples were sepa-
rated into acute phase (up to within seven days of onset 
of symptoms) and convalescent phase (more than seven 
days since onset of symptoms).
Study site - The Brazilian FD is divided into 31 regions. 
We collected samples from six public units: five hospitals 
located in different regions (Ceilândia, Guará, Taguatin-
ga, Sobradinho, and Planaltina) and the reference Central 
Public Health Laboratory of the FD (Portuguese acronym, 
LACEN-DF), for diagnosis of infectious diseases in the FD.
Suspected dengue case definition and recruitment - 
Potential participants with dengue symptoms that sponta-
neously sought treatment in the selected healthcare units 
between July 2013 and July 2014 were consecutively en-
rolled in the study. A suspected dengue case was defined 
as a patient with fever lasting up to seven days, accompa-
nied by at least two of the following symptoms: headache, 
retro-orbital pain, myalgia, arthralgia, prostration, rash and 
exposure to dengue transmission area in the last 15 days.
Sample size and reference standard - Sample size 
was calculated with the following assumptions: α = 0.05, 
desired precision = +4%, expected sensitivity = 92.9%, 
and expected specificity = 88.8%. Then, 160 positive 
samples (cases) and 240 negative samples (non-cases), as 
classified by the reference standard, would be required 
for sensitivity and specificity estimation, respectively. 
The reference standard used was a composite of MAC-
ELISA, virus isolation, and real-time polymerase chain 
reaction (RT-qPCR). Samples were considered as true-
positives (cases) when at least one of the reference tests 
had a positive result, and true-negatives (non-cases) 
when all the three reference tests were negative. All the 
reference tests were carried out in LACEN-DF.
Index test - The rapid test Bioeasy SD Dengue Duo is a 
qualitative immunoassay for simultaneous detection of NS1 
antigen, IgM antibodies and IgG antibodies for dengue in 
serum, plasma or whole blood. All samples were tested with 
the index test at the health units where the participant was 
recruited, following the instructions of the manufacturer.
Masking - Reference tests and the index test were 
performed independently and masked. Professionals 
who performed reference tests did not know the result of 
the index test and vice versa.
Reliability evaluation - The reliability between the 
results obtained in the health units and the reference lab-
oratory was evaluated in 401 samples and measured by 
the percentage of crude agreement and the kappa coef-
ficient (κ) with the respective 95% confidence intervals 
(95% CI) (Sim and Wright 2005).
Laboratory methods - For RT-qPCR, viral RNA 
from serum samples, stored in a -70ºC freezer, was ex-
tracted with the High Pure Viral Nucleic Acid Version 
18 Kit (Roche Diagnostics). The reaction was performed 
in a single step (multiplex), following the kit protocol, 
and using LightCycler ® Multiplex RNA Virus Master 
Version 03 (Roche Diagnostics). The final volume was 
20 µL, the primers’ concentrations were 0.5 µM, and 
probe concentration was 200 nM. For the interpretation 
of the results, the threshold cycle (Ct) of each reaction 
was taken into account. For Cts between 1 and 37, the 
sample was considered positive; otherwise, specimens 
were considered negative (Johnson et al. 2005).
The technique used for viral isolation from the sera 
is based on the sensitivity of Aedes albopictus cells 
(C6/36 clone) to several flaviviruses. From each serum 
sample, 20 µL was inoculated into culture tubes con-
taining C6/36 cells, which were incubated at 25ºC for 
approximately eight days. Confirmation of viral infec-
tion was obtained by indirect immunofluorescence with 
monoclonal antibodies for DENV 1, DENV 2, DENV 3, 
DENV 4 and Yellow Fever (Gubler et al. 1984).
Serology testing was carried out using MAC-ELISA, 
according to the protocol by Kuno et al. (1987). The read-
ing test was done by colorimetric methods using a spec-
trophotometer for ELISA plates (ASYS Expert Plus) with 
a 405 nm filter. The cut-off point in absorbance was 0.2.
For the implementation of the Bioeasy SD Dengue 
Duo rapid test (Standard Diagnostic Inc., Korea), all the 
manufacturer’s recommendations were followed. Visual 
interpretation of test results was done 15 to 20 minutes 
after sample addition. Samples were considered positive 
for the rapid test when a positive result was obtained for 
the NS1 and/or IgM bands.
Ethics - The Ethics Committee of the Health Secre-
tariat of the Federal District approved this project under 
the register number 20472313.3.0000.5553. Free and in-
formed consent was obtained from all participants in-
cluded in the research.
RESULTS
Of the 1,353 participants who met the suspected den-
gue case definition and were tested with the index test, 
1,222 were consecutively tested by the reference stan-
dard methodologies, resulting in the identification of 
206 cases and 246 non-cases (Fig. 1).
The characteristics of the participants are shown in 
Table I. The reference tests among cases (n = 206) showed 
positive in 143 samples for the MAC-ELISA, 58 for vi-
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ral isolation and 121 for RT-qPCR (Table II). DENV- 1, 
DENV-3 and DENV-4 were detected by RT-qPCR, with 
the highest frequency for serotype 1 in 95.04% of the 
samples. Cases and non-cases were similar with respect 
to demographic and clinical characteristics. Most cases 
and non-cases had no history of previous episodes of 
dengue at baseline. Regarding the time from onset of 
the suspected dengue syndrome, participants were clas-
sified into acute (≤ 7 days) or convalescent (> 7 days). 
Most cases and non-cases were in the acute phase, 81% 
and 79%, respectively (Table III).
Of the 246 true-negative samples, four showed a 
false-positive result to the rapid test Bioeasy SD Dengue 
Duo. Two were positive for NS1 and negative for IgM, 
and two were negative for NS1 and positive for IgM. 
Among the 206 cases, 49 samples had false negative re-
sults to the rapid test. The test accuracy parameters are 
described in Table IV.
The results of the reference tests in the 49 participants 
with false-negative results observed with the rapid test are 
demonstrated in Supplementary data (Table I). Thirty-
eight of the 49 (77,6%) samples with false-negative re-
sults were positive for the MAC-ELISA and 15 (30,6%) 
were positive for RT-qPCR. These results indicate that for 
those 49 false negative samples, 67.34% (33 samples) had 
a combination of MAC-ELISA positive, viral isolation 
negative and RT-qPCR negative reference results.
The analysis of the performance of each component 
of the rapid test demonstrated that, among 143 positive 
samples for serum IgM MAC-ELISA, only 72 (50.34%) 
were positive for the IgM component of the rapid test, 
while 90 (62.93%) positive specimens were observed for 
the NS1 component [Supplementary data (Table II)].
Fig. 1: flow diagram for the study of the accuracy of the SD Bioeasy Dengue Duo rapid test. Federal District (FD), Brazil, 2014.
TABLE I
Demographic and clinical characteristics of  
1,222 participants from Federal District (FD)  
with suspected dengue syndrome in 2014
Characteristics Values (% or SD)
Sex (%)
   Male




   Mean (SD)
   Variation




Duration of symptoms (%)
   ≤ 5 days
   > 5 days 
   Not informed
   Mean (SD)






History of previous dengue episode (%)
   Yes
   No




Public health unit (%)
   Sobradinho
   Planaltina
   Guará
   LACEN
   Taguatinga
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We also analysed the performance of the rapid test in 
different scenarios of dengue infection: acute infection, 
convalescence and participants who reported a history 
of a previous episode of dengue [Supplementary data 
(Tables III-IV)].
The rapid test showed 78.44% (131/167) sensitivity 
for acute infection when we analyse the NS1 and IgM 
components together [Supplementary data (Table III)]. 
For reinfection analysis, 148 samples were classified as 
primary dengue and 21 as secondary dengue. The sen-
sitivity of the rapid test proved to be better in primary 
dengue (77.7%) than in secondary dengue (66.7%), in-
dependent of whether the rapid test components (NS1/
IgM/IgG) were being analysed separately or together 
[Supplementary data (Table IV)].
The sensitivity of both the IgM component and the 
NS1 component gradually improved as the number of 
TABLE II
Result composition for 206 cases regarding three  
standard methodologies of reference: MAC-ELISA IgM,  
virus isolation and real-time polymerase chain reaction  
(RT-qPCR). Federal District (FD), 2014
Reference standard (composition) n (%)
Mac IgM + / Isolation - / qPCR - 84 (40.77)
Mac IgM + / Isolation - / qPCR + 50 (24.27)
Mac IgM - / Isolation + / qPCR + 48 (23.30)
Mac IgM - / Isolation - / qPCR + 14 (6.79)
Mac IgM + / Isolation + / qPCR + 9 (4.36)
Mac IgM - / Isolation + / qPCR - 1 (0.005)
Total 206 (100)
TABLE III
Clinical and demographic characteristics of cases and no cases for the validation and reliability  









   Male






   0 - 20
   21 - 40
   41 - 60
   61 - 80
   81 - 100
   Mean (SD)













31.19 (SD = 18.23)
36
Duration  of symptoms (days)
   ≤ 2
   3 - 4
   5 - 6
   ≥ 7












   Sobradinho
   Planaltina
   Guará
   LACEN
   Taguatinga













History of previous dengue episode (%)
   Yes
   No








   Acute phase
   Convalescent phase
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days from onset of symptoms to the sample collection 
day increased (Fig. 2).
Regarding the absorbance of the reference test MAC-
ELISA, the results were analysed in four groups divided 
by the intensity of the absorbance; 0.200 to 0.299; 0.300 
to 0.399; 0.400 to 0.499 and ≥ 0.500. As expected, the 
rapid test IgM component obtained a better performance 
in samples with higher absorbance intensities, from 19% 
sensitivity for absorbance levels between 0.200 to 0.299 
to 75% sensitivity for absorbance ≥ 0.500. The NS1 
component sensitivity results again showed better per-
formance than the IgM component (Fig. 3).
The sensitivity of the rapid test components in re-
lation to the RT-qPCR reference test Ct was evaluated 
measuring Cts at intervals of 10 to 20, 21 to 30 and 31 to 
37. The sensitivity of IgM increased with increasing Ct; 
the NS1 component had an inverse trend. We observed 
that the sensitivity of IgM ranged from 10% for Ct be-
tween 10 and 20 to 42% for Ct 31 to 37, while the NS1 
showed a significant decrease from 86% for Ct from 21 
to 30 to 68% for Ct 31 to 37 (Fig. 4).
The reliability study between health care settings 
with different levels of complexity was conducted for the 
IgM, NS1 and IgG components of the rapid test. We also 
analysed the agreement for samples classified as acute 
infection, that is, those positive samples for the NS1 and/
or IgM. The best agreement was found for the NS1 com-
ponent [Supplementary data (Table V)].
DISCUSSION
The Brazilian experience with RDTs is still scarce, 
and there is national recognition that their introduction 
for clinical care or surveillance purposes should be thor-
oughly assessed, especially in relation to the effects that 
these tests will have on clinical, surveillance and disease 
control practices. Thus, it is imperative to have adequate 
TABLE IV















































































PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio.
Fig. 2: sensitivity evaluation of the NS1 component, IgM component and the combination of both NS1 and IgM components of the SD Bioeasy 
Dengue Duo test according to the time from onset of symptoms to collection of the serum sample. Federal District (FD), Brazil, 2014.
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Fig. 4: sensitivity evaluation of the NS1 component, IgM component and the combination of both NS1 and IgM components of the SD Bioeasy 
Dengue Duo test according to the Ct of the reference pattern real-time polymerase chain reaction (RT-qPCR). Federal District (FD), Brazil, 2014.
Fig. 3: sensitivity evaluation of the NS1 component, IgM component and the combination of both NS1 and IgM components of the SD Bioeasy 
Dengue Duo test according to the absorbance intensity of the reference standard test MAC-ELISA-IgM. Federal District (FD), Brazil, 2014.
accuracy and reliability evaluation before their incorpo-
ration for routine use.
In this context, the present research is the first phase 
III validation study of a rapid chromatographic immuno-
assay for the diagnosis of dengue conducted in Brazil. The 
dominant feature of the approach used was the prospective 
inclusion of over a thousand participants with suspected 
dengue clinical syndrome. Previous studies carried out in 
this country used samples stored in biorepositories or bio-
banks, affecting the performance of the index test largely 
due to the bias of previous serological screening. Another 
drawback of previous studies is the failure to comply with 
the manufacturer’s instructions for rapid testing. Most of 
them require the test application in point-of-care settings, 
immediately after collection of biological samples, and not 
in frozen stored material (Boelaert et al. 2007).
Regarding the demographic and clinical characteris-
tics of the participants, the average age was 35 years and 
there was a female predominance. Similar demographic 
profiles were observed in previous studies conducted in 
the state of Minas Gerais, Brazil, making the results of 
the present study comparable (Teixeira et al. 2010).
In this context, for this target population, the over-
all sensitivity of the SD Bioeasy Dengue Duo test was 
unsatisfactory. The best performance observed for the 
sensitivity was a moderate 76% for the combination of 
NS1 and IgM components. In other studies, conducted in 
different countries, the test sensitivity was higher at 85% 
(Andries et al. 2012) and 92% (Blacksell et al. 2011). 
This heterogeneity of available accuracy data reinforces 
the importance of evaluating the accuracy of RDTs in 
the target population where the test will be applied. This 
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is relevant because of changes in genetic background, 
epidemiological and cultural conditions, among other 
factors that can directly affect the performance of RDTs. 
Specificity estimates of the SD Bioeasy Dengue Duo 
test performed well (98%), similar to other recent studies 
(Wang and Sekaran 2010, Blacksell et al. 2011).
The construction of an appropriate reference stand-
ard for validation was made possible by combining three 
reference methodologies. By comparing the three refer-
ence methodologies and the components of the rapid test, 
we were able to detect an unexpected pattern in the per-
formance of the IgM component of the rapid test. Great-
er agreement was observed between positive results for 
the NS1 component than for the IgM component of the 
rapid test in samples with confirmed infection through 
the reference standard methodology MAC-ELISA IgM. 
This phenomenon may be associated with the lower sen-
sitivity of the IgM component (35%), emphasizing the 
urgent need for improving this component.
Taking into consideration the overall accuracy in the 
present study, it can be suggested that the SD Bioeasy 
Dengue Duo test is useful to confirm but not enough 
to rule out the diagnosis of acute symptomatic dengue 
infection. This perception was confirmed by the positive 
likelihood ratio above 10 and negative likelihood ratio 
up to 0.1 (Grimes and Schulz 2005).
Currently, most rapid tests used in Brazil for the di-
agnosis of dengue are used in primary care settings as 
screening tests, despite their low sensitivity. Thus, the im-
plementation of diagnostic tests without proper validation 
can bring new challenges to the health system. If rapid 
tests with unsatisfactory accuracy for the timely detection 
and management of cases were incorporated into health 
systems, we may have an increase in lethal outcomes.
The performance of the IgM and NS1 components 
together showed better results for acute compared to 
convalescent infection. In a study published in 2010 by 
Wang and Sekaran, similar data were observed. For the 
NS1 component, the sensitivity for acute and convalescent 
infection was 100% and 70%, respectively (Wang and Se-
karan 2010). The lower sensitivity of the NS1 component 
of the test in relation to previous exposure to dengue in-
fection may reflect the lower antigen levels common in 
people with reinfection (Bäck and Lundkvist 2013).
The analysis related to the period from symptoms 
onset to the time of sample collection demonstrated that 
the IgM component behaviour was consistent with the 
dynamics of infection by DENV. Our results demon-
strated sensitivity that was directly proportional to the 
interval between the onset of symptoms and the collec-
tion of the sample. For the analysis combining NS1 and 
IgM results, there were no major variations in test sensi-
tivity at any period of infection.
This study also provides data on the relationship be-
tween the magnitude of the antibody response and the 
positivity of the rapid test. The results showed that for 
NS1, IgM and IgM/NS1, components there was an im-
provement in test sensitivity when the concentration of 
IgM in the patient serum was greater. The results for the 
IgM test component were very consistent, demonstrating 
a direct relation to the intensity of the absorbance values.
We show, in this study, that the sensitivity of the rap-
id test components is directly related to the viral RNA 
concentration in positive samples. We observed a de-
crease in sensitivity of the NS1 component at a higher 
Ct. Lower Ct reflects a higher concentration of virus in 
the patient samples, and thus a higher concentration of 
viral antigens, such as the NS1 protein. These results 
demonstrate that the dynamics of patient infection di-
rectly affect the test results (Bäck and Lundkvist 2013).
We demonstrated a high reproducibility of the rap-
id test between the patient’s point-of-care and reference 
laboratory results, reinforcing the potential usefulness of 
the test in the context of primary healthcare. The unsatis-
factory results for the IgM component (Kappa = 0.5) and 
IgG component (Kappa = 0.75) may be expressing the in-
fluence of disease prevalence, reflecting the phenomenon 
known as Kappa paradox. When the prevalence rate is 
high, the correlation due to chance is high and, therefore, 
the Kappa will be lower (Sim and Wright 2005).
In conclusion, the rapid SD Bioeasy Dengue Duo 
test has high specificity and moderate sensitivity, and 
the values of the observed likelihood ratios suggest that 
the test is useful to confirm the diagnosis of dengue, but 
not enough to rule out such diagnosis and should be im-
proved in respect to sensitivity. The combination of the 
two components, NS1 and IgM, had the best accuracy 
compared to the NS1 and IgM component performance 
when used separately. Our results are applicable to sim-
ilar scenarios with transmission of DENV1 and should 
be applied cautiously in scenarios with significant cir-
culation of DENV4, which has been reported as more 
challenging for achieving reasonable rapid test accuracy 
(Colombo et al. 2013, Acosta et al. 2014, Buonora et al. 
2016). Regarding the dynamics of infection by DENV 
and immunological response, it may be concluded that 
patients who have triggered a greater immune response 
with higher concentrations of IgM and a higher viral 
load in blood are more likely to have positive results for 
the SD Bioeasy Dengue Duo rapid test. Reproducibil-
ity between observers of the selected health units and 
observers of the reference laboratory was satisfactory, 
reinforcing the test usefulness as a point-of-care test in 
the context of primary healthcare settings.
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